The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure

European Journal of Human Genetics

Volumn 14, Issue 7, 2006, Pages 860-866

  Schelleman, Hedi ^a,b   Klungel, Olaf H ^b   Witteman, Jacqueline C M ^a   Hofman, Albert ^a   van Duijn, Cornelia M ^a   de Boer, Anthonius ^b   Stricker, Bruno H C H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alpha adducin; Angiotensinogen; Antihypertensive drugs; Blood pressure; Drug gene interaction

Indexed keywords

ADDUCIN; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHIONINE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN SUBUNIT; THREONINE; TRYPTOPHAN;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ALPHA CHAIN; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; ESSENTIAL HYPERTENSION; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; STATISTICAL MODEL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CALMODULIN-BINDING PROTEINS; COHORT STUDIES; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 33745257301     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201632     Document Type: Article

References (20)

1. Cusi D, Barlassina C, Azzani T et al: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-1357.
2. Glorioso N, Manunta P, Filigheddu F et al: The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34 (Part 1): 649-654.
3. Sciarrone MT, Stella P, Barlassina C et al: ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41: 398-403.
4. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E: Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16: 834-839.
5. Matayoshi T, Kamide K, Takiuchi S et al: The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res 2004; 27: 821-833.
6. Psaty BM, Smith NL, Heckbert SR et al: Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287: 1680-1689.
7. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13 (Part 2): 1602-1609.
8. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of rennin-angiotensin system genes. J Hypertens 1996; 14: 259-262.
9. Kurland L, Melhus H, Karlsson J et al: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783-1787.
10. Bozec E, Fassot C, Tropeano AI et al: Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clin Sci (London) 2003; 105: 637-644.
11. Bis JC, Smith NL, Psaty BM et al: Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003; 16: 1011-1017.
12. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA: Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-422.
13. Anonymous: Guidelines for ATC Classification and DDD Assignment, 3rd edn. Oslo: WHO collaberating Centre for drug statistics Methodology, 2000.
14. van Duijn CM, de Knijff P, Cruts M et al: Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994; 7: 74-78.
15. Bianchi G, Tripodi G, Casari G et al: Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 1994; 91: 3999-4003.
16. Wang JG, Staessen JA, Barlassina C et al: Association between hypertension and variation in the alpha- and beta-adducin genes in a white population. Kidney Int 2002; 62: 2152-2159.
17. Province MA, Arnett DK, Hunt SC et al: Association between the alpha-adducin gene and hypertension in the HyperGEN Study. Am J Hypertens 2000; 13 (Part 1): 710-718.
18. Ferreri NR, Zhao Y, Takizawa H, McGiff JC: Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens 1997; 15 (Part 1): 1481-1484.
19. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al: Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992; 71: 169-180.
20. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A: Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23: 1269-1275.